ERMEZA Drug Patent Profile
✉ Email this page to a colleague
When do Ermeza patents expire, and when can generic versions of Ermeza launch?
Ermeza is a drug marketed by Mylan and is included in one NDA. There is one patent protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in ERMEZA is levothyroxine sodium. There are ten drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ermeza
A generic version of ERMEZA was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERMEZA?
- What are the global sales for ERMEZA?
- What is Average Wholesale Price for ERMEZA?
Summary for ERMEZA
| International Patents: | 7 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for ERMEZA |
| What excipients (inactive ingredients) are in ERMEZA? | ERMEZA excipients list |
| DailyMed Link: | ERMEZA at DailyMed |
Pharmacology for ERMEZA
| Drug Class | l-Thyroxine |
US Patents and Regulatory Information for ERMEZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | ERMEZA | levothyroxine sodium | SOLUTION;ORAL | 215809-001 | Apr 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ERMEZA
See the table below for patents covering ERMEZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 3261676 | FORMULATIONS LIQUIDES DE LÉVOTHYROXINE (LIQUID LEVOTHYROXINE FORMULATIONS) | ⤷ Sign Up |
| Croatia | P20201354 | ⤷ Sign Up | |
| Spain | 2814129 | ⤷ Sign Up | |
| Slovenia | 3261676 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2016137969 | ⤷ Sign Up | |
| Montenegro | 03810 | TEKUĆE FORMULACIJE LEVOTIROKSINA (LIQUID LEVOTHYROXINE FORMULATIONS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
